Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Genzyme Braces For Icahn Bid

by Rick Mullin
March 1, 2010 | A version of this story appeared in Volume 88, Issue 9

Activist investor Carl Icahn has notified Genzyme that he intends to nominate himself and three others to Genzyme’s board of directors at the biotech firm’s 2010 shareholders meeting, scheduled for May 20. Genzyme says the board’s nominating and governance committee will evaluate the bid. Verin Mehta, managing member of investment advisers Mehta Partners, notes that Genzyme’s credibility was shaken following a virus contamination at its Allston, Mass., facility. “Cleaning up a rare virus in manufacturing is a challenge, but Genzyme took longer than it had initially hoped,” Mehta says. “But our view is that management has done a good job and that that will be reflected in shareholders’ votes.”

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.